Right to Information Act – overview and applications MCQs With Answer

The Right to Information Act – overview and applications MCQs With Answer is a practical guide for B.Pharm students to understand RTI basics, legal provisions, and how transparency affects pharmaceutical regulation. This introduction covers RTI scope, key authorities, timelines, exemptions, and penalties, with pharmacy-relevant examples such as access to drug approval records, clinical trial permissions, procurement documents, and public health data. Knowing how to file requests, identify Public Information Officers (PIOs), and interpret exemptions helps future pharmacists engage in ethical practice, ensure regulatory compliance, and promote accountability in drug safety and public procurement. Now let’s test your knowledge with 30 MCQs on this topic.

Q1. What year was the Right to Information (RTI) Act enacted in India?

  • 2000
  • 2005
  • 2010
  • 1995

Correct Answer: 2005

Q2. Who is eligible to file an RTI application under the RTI Act?

  • Only Indian citizens
  • Any person including foreign nationals
  • Only government employees
  • Only legal professionals

Correct Answer: Any person including foreign nationals

Q3. Which official is primarily responsible for receiving and responding to RTI applications in a public authority?

  • First Appellate Authority
  • Public Information Officer (PIO)
  • Central Information Commissioner
  • Head Clerk

Correct Answer: Public Information Officer (PIO)

Q4. What is the standard time limit for a PIO to provide information under the RTI Act?

  • 15 days
  • 30 days
  • 60 days
  • 90 days

Correct Answer: 30 days

Q5. When does the RTI Act require information to be provided within 48 hours?

  • For all RTI applications
  • When information concerns life or liberty of a person
  • For applications about drug pricing only
  • When the applicant is a medical practitioner

Correct Answer: When information concerns life or liberty of a person

Q6. Which section of the RTI Act broadly lists exemptions where information may be withheld?

  • Section 4
  • Section 8
  • Section 19
  • Section 2

Correct Answer: Section 8

Q7. Under the RTI Act, which of the following is considered a public authority?

  • Private retail pharmacy with no government funding
  • Government-run drug procurement agency
  • Foreign pharmaceutical company with no Indian operations
  • Private clinic wholly funded by patients

Correct Answer: Government-run drug procurement agency

Q8. Can RTI be used to access clinical trial approval documents held by a regulatory authority?

  • No, clinical trial documents are always exempt
  • Yes, subject to exemptions like commercial confidence and personal privacy
  • Only if the trial failed
  • Yes, but only by the trial sponsor

Correct Answer: Yes, subject to exemptions like commercial confidence and personal privacy

Q9. Which body hears appeals if an applicant is dissatisfied with PIO’s RTI response at the central level?

  • Central Information Commission
  • Supreme Court
  • State Governor
  • Public Accounts Committee

Correct Answer: Central Information Commission

Q10. What is the penalty a PIO can be fined for unreasonable delay or incorrect information (per day)?

  • Rs 100 per day
  • Rs 250 per day
  • Rs 500 per day
  • Rs 1000 per day

Correct Answer: Rs 250 per day

Q11. In a pharmaceutical context, which of the following RTI requests is most likely to be allowed?

  • Trade secrets of a private manufacturer
  • Government tender documents for public drug procurement
  • Personal medical records of another patient
  • Unpublished proprietary R&D protocols

Correct Answer: Government tender documents for public drug procurement

Q12. How long does an applicant have to file a first appeal under the RTI Act?

  • 15 days from receipt of decision
  • 30 days from receipt of decision
  • 60 days from receipt of decision
  • 90 days from receipt of decision

Correct Answer: 30 days from receipt of decision

Q13. Which of the following types of information can be refused under the RTI Act on grounds of “commercial confidence”?

  • Manufacturer’s trade secrets disclosed to a regulatory body
  • Basic drug approval status
  • Publicly available price list
  • Government policy documents

Correct Answer: Manufacturer’s trade secrets disclosed to a regulatory body

Q14. Who is the First Appellate Authority in a public authority?

  • The same person as the PIO
  • An officer designated to hear first appeals within the public authority
  • The Central Information Commissioner
  • The police superintendent

Correct Answer: An officer designated to hear first appeals within the public authority

Q15. Does the RTI Act allow access to one’s own medical records held by a public hospital?

  • No, medical records are always exempt
  • Yes, an individual can obtain their own medical records
  • Only with a court order
  • Only if the hospital is privately funded

Correct Answer: Yes, an individual can obtain their own medical records

Q16. What is the role of the Central/State Information Commission under RTI?

  • To draft pharmaceutical policies
  • To adjudicate second appeals and monitor compliance
  • To license pharmacies
  • To conduct criminal investigations

Correct Answer: To adjudicate second appeals and monitor compliance

Q17. Which of the following is a valid ground for rejection of an RTI application?

  • Applicant requested information in a vague, unclear manner
  • Information is already in the public domain
  • Information would cause harm to national security (as exempted)
  • All of the above

Correct Answer: All of the above

Q18. Can RTI be used to obtain details of adverse drug reaction reports maintained by a government body?

  • No, pharmacovigilance data is always secret
  • Yes, subject to patient privacy and exemption considerations
  • Only by pharmaceutical companies
  • Only if the drug is banned

Correct Answer: Yes, subject to patient privacy and exemption considerations

Q19. Which section of the RTI Act provides for appointment of Central and State Information Commissioners?

  • Section 12
  • Section 15
  • Section 17
  • Section 21

Correct Answer: Section 15

Q20. If a PIO fails to provide information within the statutory time, what remedy does the applicant have?

  • File a complaint to the police
  • File an appeal to the First Appellate Authority or directly to Information Commission after timelines
  • No remedy available
  • File for bankruptcy

Correct Answer: File an appeal to the First Appellate Authority or directly to Information Commission after timelines

Q21. Which of the following is true about third-party information under RTI?

  • PIO must always disclose third-party information without notice
  • PIO should notify the third party if disclosure affects their commercial confidence
  • Third-party information is never disclosable
  • Third parties cannot participate in appeals

Correct Answer: PIO should notify the third party if disclosure affects their commercial confidence

Q22. In the context of drug regulation, RTI can help students and professionals by providing access to:

  • Confidential patient names from a private clinic
  • Regulatory inspection reports of government-run drug stores
  • Proprietary manufacturing formulas of private firms
  • Personal emails of drug inspectors unrelated to work

Correct Answer: Regulatory inspection reports of government-run drug stores

Q23. What is the maximum penalty amount a PIO can be directed to pay under RTI for non-compliance?

  • Rs 5,000
  • Rs 10,000
  • Rs 25,000
  • Rs 50,000

Correct Answer: Rs 25,000

Q24. Which of the following must a public authority proactively publish under Section 4 of the RTI Act?

  • Manuals, rules, and procedures relevant to public
  • Personal email correspondence of officers
  • Private commercial contracts of third parties only
  • Medical histories of patients

Correct Answer: Manuals, rules, and procedures relevant to public

Q25. Are research data and results generated by a government-funded pharmaceutical study accessible under RTI?

  • Never accessible
  • Accessible, but may be limited by exemptions like commercial confidence or national security
  • Only accessible to foreign researchers
  • Only accessible after 50 years

Correct Answer: Accessible, but may be limited by exemptions like commercial confidence or national security

Q26. Which authority can impose disciplinary action or penalty on a PIO for RTI violations?

  • Central/State Information Commission
  • Local municipal council
  • Pharmacy Council
  • Drug Controller General

Correct Answer: Central/State Information Commission

Q27. What should an RTI application ideally include to be effective?

  • Vague request without specifying documents
  • Clear description of information sought, applicant details, and contact information
  • Demand for illegal disclosure
  • Only a photograph

Correct Answer: Clear description of information sought, applicant details, and contact information

Q28. Can decisions of regulatory bodies like CDSCO be challenged or information sought via RTI?

  • RTI cannot be used against CDSCO
  • Yes, information held by CDSCO can be sought under RTI subject to exemptions
  • Only courts can access CDSCO records
  • Only licensed pharmacists can file such RTIs

Correct Answer: Yes, information held by CDSCO can be sought under RTI subject to exemptions

Q29. Which of the following best describes “information” under the RTI Act?

  • Only printed documents
  • Any material in any form, including records, memos, emails, opinions, and data
  • Only verbal statements in court
  • Only personal handwritten notes of citizens

Correct Answer: Any material in any form, including records, memos, emails, opinions, and data

Q30. How does RTI support ethical practice in the pharmaceutical sector for B.Pharm students?

  • By encouraging secrecy and withholding information
  • By promoting transparency in drug approval, procurement, and safety monitoring, enabling informed professional conduct
  • By providing free drugs to students
  • By replacing regulatory inspections entirely

Correct Answer: By promoting transparency in drug approval, procurement, and safety monitoring, enabling informed professional conduct

Leave a Comment